Macquarie has described the near-term outlook for Australian medical equipment firm Ansell (ASX:ANN) as ‘uncertain’, despite the forecasts capturing an improved growth from the financial year 2025.

On the other hand, for the biotechnology company CSL (ASX:CSL), the brokerage is expecting growth, factoring in the recovery of its base business, irrespective of its weaker-than-anticipated guidance for the financial year 2024.

Macquarie also anticipates a downside risk to the current financial year 2023 consensus EPS forecasts for Ramsay Health Care (ASX:RHC) and Sonic Healthcare (ASX:SHL).

It believes the potential sale of Ramsay’s Asia-focused joint venture with Malaysia’s Sime Darby could address its recent balance sheet concerns.

Macquarie opines that Regis Healthcare’s (ASX:REG) growth is influenced by a positive outlook for residential aged care, bolstered by favourable industry fundamentals and improved government funding.

As of the last market close, ANN shares were down by 15.2%, CSL shares fell by 6.8%, RHC shares dipped by 9.6%, while SHL and REG shares went up by 15.2% and 19.9%, respectively.

Ansell (ASX:ANN) is a leading Australian medical equipment firm.